Skin repair specialist Avita Medical says the start of a clinical trial on vitiligo patients in the US this week brings it closer to commercialising its Recell treatment for vitiligo sufferers in that market.
Vitiligo is one of the world's commonest skin pigmentation disorders, which is estimated to affect 6.5 million Americans, and up to 2 per cent of the world's population.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
